Eckhoff Courtney D, Didomenico Robert J, Shapiro Nancy L
Department of Pharmacy Practice, University of Illinois at Chicago, 833 S. Wood St, Chicago, IL 60612-7230, USA.
Ann Pharmacother. 2004 Dec;38(12):2115-21. doi: 10.1345/aph.1E083. Epub 2004 Nov 2.
To review the literature investigating initial dosing of warfarin at 5 or 10 mg for treatment of acute venous thromboembolism.
Articles were identified through searches of MEDLINE (1966-December 2003) using the key words warfarin, oral anticoagulation, warfarin dose, warfarin initiation, venous thromboembolism, and anticoagulation. Additional references were located through review of the bibliographies of the articles cited.
Studies of the initial dosing of warfarin at 5 or 10 mg were evaluated and relevant information was included, as were those that identified known factors that influence the maintenance dose of warfarin.
For the treatment of acute venous thromboembolism, warfarin dosing is often provider dependent. Until recently, studies suggested that 5 mg initiation was as effective as 10 mg, without increasing the risk of bleeding. However, the most recent study comparing a 5- versus 10-mg initial dosing nomogram supports an initial dose of 10 mg. These results should be interpreted with caution, however, since patients at high risk for bleeding were excluded from the study. Several patient-specific factors will affect the maintenance dose, guiding clinicians to start with lower (<5 mg) or higher (>5 mg) doses.
Although recent evidence supports a 10-mg initiation nomogram, clinicians should consider patient-specific factors prior to deciding an initial warfarin dose. If a 10-mg loading dose is utilized, strict compliance with the protocol is necessary.
回顾关于华法林初始剂量为5毫克或10毫克用于治疗急性静脉血栓栓塞症的文献研究。
通过检索MEDLINE(1966年至2003年12月),使用关键词华法林、口服抗凝、华法林剂量、华法林起始、静脉血栓栓塞症和抗凝来识别文章。通过查阅所引用文章的参考文献找到其他相关文献。
对华法林初始剂量为5毫克或10毫克的研究进行评估,并纳入相关信息,以及那些识别出影响华法林维持剂量的已知因素的研究。
对于急性静脉血栓栓塞症的治疗,华法林的剂量通常取决于医疗服务提供者。直到最近,研究表明起始剂量为5毫克与10毫克的效果相同,且不会增加出血风险。然而,最近一项比较5毫克与10毫克初始剂量方案的研究支持初始剂量为10毫克。不过,这些结果应谨慎解读,因为该研究排除了出血高风险患者。几个患者特异性因素会影响维持剂量,指导临床医生从较低(<5毫克)或较高(>5毫克)剂量开始。
尽管最近的证据支持10毫克起始剂量方案,但临床医生在决定华法林初始剂量之前应考虑患者特异性因素。如果采用10毫克的负荷剂量,必须严格遵守方案。